Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

Pancreas. 2009 Jan;38(1):78-84. doi: 10.1097/mpa.0b013e318183d72f.

Abstract

Objectives: Pancreatic cancer is one of the leading causes of cancer related deaths in the western world. It is also resistant to most chemotherapeutic modalities. Phosphodiesterase-4 inhibitors (PDE4is) have found applications in the treatment of respiratory diseases. The aim of this study is to investigate the cytotoxic effect of 2 novel PDE4is, the CC-8075 and CC-8062 compounds in pancreatic cancer cells.

Methods: Cell proliferation was measured using the sulforhodamine B protein dye. Induction of apoptosis was detected using enzyme-linked immunosorbent assay. Regulation of proteins and posttranslational modifications were determined using immunoblotting.

Results: Treatment of pancreatic cancer cells with CC-8075 and CC-8062 reduces their proliferation and increases apoptosis that is caspase dependent in T3M4 cells. Furthermore, PDE4is increase phosphorylation of p38MAPK, mitogen-activated protein kinase (MAPK) kinase 3/6,MAPKYactivated protein kinase 2, Atf2, and Hsp27. The use of thep38MAPK-specific inhibitors SB202190 and SB203580 results in a modest reduction in PDE4i-induced apoptosis in T3M4 cells. Also, retinoids enhance apoptosis induced by CC-8075 and CC-8062 in GER cells.

Conclusions: These results highlight the antiproliferative effects of the phosphodiesterase inhibitors CC-8075 and CC-8062 in pancreatic cancer cells and suggest that activation of p38MAPK signaling pathway may be associated with this process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alitretinoin
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Imidazoles / pharmacology
  • Pancreatic Neoplasms / enzymology
  • Pancreatic Neoplasms / pathology*
  • Phosphodiesterase 4 Inhibitors*
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / pharmacology
  • Signal Transduction / drug effects
  • Tretinoin / pharmacology
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Phosphodiesterase 4 Inhibitors
  • Phosphodiesterase Inhibitors
  • Protein Kinase Inhibitors
  • Pyridines
  • Alitretinoin
  • Tretinoin
  • p38 Mitogen-Activated Protein Kinases
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • SB 203580
  • 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole